Results from an external proficiency testing program

11 years of molecular genetics testing for myotonic dystrophy type 1

Carolyn (Sue) Richards, Glenn E. Palomaki, Madhuri Hegde

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose:The aim of this study was to examine the performance of laboratories offering assessment for myotonic dystrophy type 1 (DM1) using external proficiency testing samples. DM1, a dominant disorder, has a prevalence of 1:20,000 due to the expansion of CTG trinucleotide repeats in the DMPK gene.Methods:External proficiency testing administered by the College of American Pathologists/American College of Medical Genetics and Genomics distributes three samples twice yearly. Responses from 2003 through the first distribution of 2013 were analyzed after stratification by location (United States/international). Both the repeat sizes (analytic validity) and clinical interpretations were assessed.Results:Over the 21 distributions, 45 US and 29 international laboratories participated. Analytic sensitivity for detecting and reporting expanded repeats (≥50) was 99.2% (382/385 challenges) and 97.1% (133/137 challenges), respectively. Analytic specificity (to within two repeats of the consensus) was 99.2% (1,790/1,805 alleles) and 98.6% (702/712 alleles), respectively. Clinical interpretations were correct for 99.3% (450/453) and 98.2% (224/228) of positive challenges and in 99.9% (936/937) and 99.6% (455/457) of negative challenges, respectively. Of four incorrect interpretations made in the United States, two were probably due to sample mix-up.Conclusion:This review of laboratory performance regarding laboratory-developed genetic tests indicates very high performance for both the analytic and interpretative challenges for DM1.

Original languageEnglish (US)
Pages (from-to)1290-1294
Number of pages5
JournalGenetics in Medicine
Volume18
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Myotonic Dystrophy
Genetic Testing
Molecular Biology
Alleles
Trinucleotide Repeat Expansion
Genomics
Genes

Keywords

  • External proficiency testing
  • myotonic dystrophy type 1
  • trinucleotide repeats

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Results from an external proficiency testing program : 11 years of molecular genetics testing for myotonic dystrophy type 1. / Richards, Carolyn (Sue); Palomaki, Glenn E.; Hegde, Madhuri.

In: Genetics in Medicine, Vol. 18, No. 12, 01.12.2016, p. 1290-1294.

Research output: Contribution to journalArticle

@article{c64d3f04e48547fe81c2efc63307215f,
title = "Results from an external proficiency testing program: 11 years of molecular genetics testing for myotonic dystrophy type 1",
abstract = "Purpose:The aim of this study was to examine the performance of laboratories offering assessment for myotonic dystrophy type 1 (DM1) using external proficiency testing samples. DM1, a dominant disorder, has a prevalence of 1:20,000 due to the expansion of CTG trinucleotide repeats in the DMPK gene.Methods:External proficiency testing administered by the College of American Pathologists/American College of Medical Genetics and Genomics distributes three samples twice yearly. Responses from 2003 through the first distribution of 2013 were analyzed after stratification by location (United States/international). Both the repeat sizes (analytic validity) and clinical interpretations were assessed.Results:Over the 21 distributions, 45 US and 29 international laboratories participated. Analytic sensitivity for detecting and reporting expanded repeats (≥50) was 99.2{\%} (382/385 challenges) and 97.1{\%} (133/137 challenges), respectively. Analytic specificity (to within two repeats of the consensus) was 99.2{\%} (1,790/1,805 alleles) and 98.6{\%} (702/712 alleles), respectively. Clinical interpretations were correct for 99.3{\%} (450/453) and 98.2{\%} (224/228) of positive challenges and in 99.9{\%} (936/937) and 99.6{\%} (455/457) of negative challenges, respectively. Of four incorrect interpretations made in the United States, two were probably due to sample mix-up.Conclusion:This review of laboratory performance regarding laboratory-developed genetic tests indicates very high performance for both the analytic and interpretative challenges for DM1.",
keywords = "External proficiency testing, myotonic dystrophy type 1, trinucleotide repeats",
author = "Richards, {Carolyn (Sue)} and Palomaki, {Glenn E.} and Madhuri Hegde",
year = "2016",
month = "12",
day = "1",
doi = "10.1038/gim.2016.59",
language = "English (US)",
volume = "18",
pages = "1290--1294",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Results from an external proficiency testing program

T2 - 11 years of molecular genetics testing for myotonic dystrophy type 1

AU - Richards, Carolyn (Sue)

AU - Palomaki, Glenn E.

AU - Hegde, Madhuri

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Purpose:The aim of this study was to examine the performance of laboratories offering assessment for myotonic dystrophy type 1 (DM1) using external proficiency testing samples. DM1, a dominant disorder, has a prevalence of 1:20,000 due to the expansion of CTG trinucleotide repeats in the DMPK gene.Methods:External proficiency testing administered by the College of American Pathologists/American College of Medical Genetics and Genomics distributes three samples twice yearly. Responses from 2003 through the first distribution of 2013 were analyzed after stratification by location (United States/international). Both the repeat sizes (analytic validity) and clinical interpretations were assessed.Results:Over the 21 distributions, 45 US and 29 international laboratories participated. Analytic sensitivity for detecting and reporting expanded repeats (≥50) was 99.2% (382/385 challenges) and 97.1% (133/137 challenges), respectively. Analytic specificity (to within two repeats of the consensus) was 99.2% (1,790/1,805 alleles) and 98.6% (702/712 alleles), respectively. Clinical interpretations were correct for 99.3% (450/453) and 98.2% (224/228) of positive challenges and in 99.9% (936/937) and 99.6% (455/457) of negative challenges, respectively. Of four incorrect interpretations made in the United States, two were probably due to sample mix-up.Conclusion:This review of laboratory performance regarding laboratory-developed genetic tests indicates very high performance for both the analytic and interpretative challenges for DM1.

AB - Purpose:The aim of this study was to examine the performance of laboratories offering assessment for myotonic dystrophy type 1 (DM1) using external proficiency testing samples. DM1, a dominant disorder, has a prevalence of 1:20,000 due to the expansion of CTG trinucleotide repeats in the DMPK gene.Methods:External proficiency testing administered by the College of American Pathologists/American College of Medical Genetics and Genomics distributes three samples twice yearly. Responses from 2003 through the first distribution of 2013 were analyzed after stratification by location (United States/international). Both the repeat sizes (analytic validity) and clinical interpretations were assessed.Results:Over the 21 distributions, 45 US and 29 international laboratories participated. Analytic sensitivity for detecting and reporting expanded repeats (≥50) was 99.2% (382/385 challenges) and 97.1% (133/137 challenges), respectively. Analytic specificity (to within two repeats of the consensus) was 99.2% (1,790/1,805 alleles) and 98.6% (702/712 alleles), respectively. Clinical interpretations were correct for 99.3% (450/453) and 98.2% (224/228) of positive challenges and in 99.9% (936/937) and 99.6% (455/457) of negative challenges, respectively. Of four incorrect interpretations made in the United States, two were probably due to sample mix-up.Conclusion:This review of laboratory performance regarding laboratory-developed genetic tests indicates very high performance for both the analytic and interpretative challenges for DM1.

KW - External proficiency testing

KW - myotonic dystrophy type 1

KW - trinucleotide repeats

UR - http://www.scopus.com/inward/record.url?scp=85000443609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000443609&partnerID=8YFLogxK

U2 - 10.1038/gim.2016.59

DO - 10.1038/gim.2016.59

M3 - Article

VL - 18

SP - 1290

EP - 1294

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 12

ER -